Voxilaprevir

Voxilaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor (by Gilead) that is used in combination with sofosbuvir and velpatasvir. The combination has the trade name Vosevi and received a positive opinion from the European Committee for Medicinal Products for Human Use in June 2017.[2]

Voxilaprevir
Clinical data
Trade namesVosevi (combination with sofosbuvir and velpatasvir)
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
PDB ligand
Chemical and physical data
FormulaC40H52F4N6O9S
Molar mass868.94 g·mol−1
3D model (JSmol)
    Density1.4±0.1[1] g/cm3

    On 18 July 2017, Vosevi was approved by Food and drug administration.[3]

    References


    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.